The Shotlee Journal
Expert insights on GLP-1 medications, peptide therapy, and evidence-based approaches to weight management.
Loading articles...
Showing 9 / 1275 articles
Stopping Ozempic can lead to full weight regain in about 1.7 years, plus reversal of cardiovascular and metabolic benefits, warns a major BMJ review. Nearly 50% of users discontinue within a year due to side effects and high costs. Doctors urge consulting before quitting to protect your health gains.
Jessica Layeux spent 15 months on Zepbound with minimal weight loss, joining 1 in 10 clinical trial non-responders who lose less than 5% body weight. Scientists are investigating genetics, hormones, and other factors behind why these popular GLP-1 drugs don't work for everyone. This guide explains the science and next steps for patients.
This awards season, Hollywood red carpets showcase pin-thin silhouettes from Emma Stone to Jenna Ortega, fueled by Ozempic microdosing. Stylists fear stars are unaware of their extreme thinness, while nutritionists spot muscle wasting and malnutrition signs. As body positivity fades, insiders reveal the pressure and health toll.
For decades, GLP-1 receptor agonists like Ozempic have transformed diabetes and obesity treatment via injections, but patients crave oral options. This guide traces the scientific quest for oral GLP-1s, from early discoveries and Gila monster breakthroughs to Rybelsus challenges and promising algae-based innovations. Understand the barriers and what's next for affordable, pill-based metabolic health.
Obesity rates hit 40% in 2022, but GLP-1 drugs are turning the tide with 15-20% weight loss. USC Schaeffer Center research shows broad access could add nearly two years of life for young adults and save Medicare $175-245 billion. Yet, limited insurance coverage blocks millions from these life-changing treatments.
Layla Taylor, star of The Secret Lives of Mormon Wives, has stepped away from GLP-1 medications after using them as an unhealthy crutch for her lifelong eating disorder. Ahead of season 4, she opens up about hidden side effects like aching joints, falling hair, and constant fatigue that signaled her body was breaking down. Her story underscores the importance of monitoring GLP-1 use, especially with pre-existing conditions.
Two women were rushed to the hospital and intubated after receiving peptide injections at a Las Vegas anti-aging festival. Nevada regulators fined providers $35,000 for unlicensed practice and wholesaling. This incident highlights the dangers of unregulated peptides promoted for anti-aging.
The surge in GLP-1 drug use among 12% of Americans is upending the food industry, with sauce and spice makers like Bachan's and Tapatio attracting high-value deals. As these medications dull taste buds and spur lean protein consumption, condiment companies are seeing explosive growth. Fast-food giants face billions in losses while flavor enhancers thrive.
Eli Lilly, maker of Mounjaro and Zepbound, has discovered critical impurities in counterfeit tirzepatide versions mixed with vitamin B12. These compounded drugs pose unknown risks due to chemical reactions and lack of FDA oversight. With one in eight Americans using GLP-1s, experts urge sticking to approved medications.
